Pipeline

Advanced clinical-stage pipeline in gastrointestinal
inflammation and infection

Leveraging our product engine, we have developed a late-stage pipeline of wholly-owned defined bacterial consortia candidates.

Program
Indication
Preclinical
CMC
Phase 1
Phase 2
Phase 3
RIGHTS

GI INFLAMMATION & IMMUNOLOGY

Program:

VE202

Indication:

Mild-to-Moderate 
Ulcerative Colitis

Progress:

Phase 2

Rights:

GI INFECTION PREVENTION

Program:

VE303

Indication:

Recurrent C. difficile Infection

Progress:

Phase 3

Rights:

Program:

VE707

Indication:

Gram-negative 
AMR Infections

Progress:

CMC

Rights:

CMC: chemistry, manufacturing and controls; AMR: antimicrobial-resistant

Our clinical candidates are potential first-in-class Live Biotherapeutic Products (LBP), a category of therapeutics that the U.S. Food and Drug Administration (FDA) uses to denote a biologic product that: 1) contains live organisms, such as bacteria; 2) is applicable to the prevention, treatment, or cure of a disease or condition of human beings; and 3) is not a vaccine.

Clinical Trials

Clinical Research Study
for Ulcerative Colitis

Phase 3 Study for
Prevention of Recurrent CDI